Tumor News and Research

RSS

Researchers refine breast cancer risk model to give more accurate assessment

A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial, known to doctors as trial EAY131, is open through the ECOG-ACRIN Cancer Research Group.

18 Aug 2015

Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

Revolutionary genetic test, Oncotype DX from Genomic Health, is now offered at Dr. Samadi's Prostate Cancer Center in New York City.

18 Aug 2015

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

A study from Massachusetts General Hospital Cancer Center researchers - the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients - reveals not only specific structural changes within patients' brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased.

18 Aug 2015

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.

18 Aug 2015

Studies show jumping genes more active during development of gastrointestinal cancers

Results of a trio of studies done on human cancer tissue biopsies have added to growing evidence that a so-called jumping gene called LINE-1 is active during the development of many gastrointestinal cancers.

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.

17 Aug 2015

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

The Idaho Society of Clinical Oncology held its annual Board of Directors retreat in Sun Valley, ID on July 24-26, 2015. The focus for the retreat was how to discuss strategies to improve the care of cancer patients in Idaho. During the meeting, ISCO board announced a partnership with the Seattle Cancer Care Alliance to collaborate with ISCO's monthly virtual personalized tumor board.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Protein Kinase C (PKC) is a family of enzymes that controls the activity of other proteins in a cell by attaching chemical tags. That simple act helps determine cell survival or death.

14 Aug 2015

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

14 Aug 2015

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.

14 Aug 2015

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

14 Aug 2015

New endoscopic system differentiates between malignant and benign tumors in gastrointestinal tract

Cancer or no cancer? This question can usually only be answered after a days-long wait for a histological examination. With the use of a mass spectrometric technique, the answer may soon be available in real time.

13 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

Researchers reveal cellular origin of PIK3CA-induced breast tumors

In a study published in Nature, researchers lead by Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Université libre de Bruxelles, Belgium, in collaboration with Pr Wayne Phillips, Australia and Pr Christos Sotiriou, Bordet Institute, Belgium, uncovered the cellular origin of PIK3CA-induced breast tumors and demonstrated that the cancer cell of origin controls tumor heterogeneity and is associated with different breast tumors types and clinical prognosis.

13 Aug 2015

FGF protein may play key role in breast and prostate cancer, shows research

Simply put, cancer is caused by mutations to genes within a cell that lead to abnormal cell growth. Finding out what causes that genetic mutation has been the holy grail of medical science for decades.

13 Aug 2015

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia.

13 Aug 2015

Tumor News and Research

Researchers refine breast cancer risk model to give more accurate assessment

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Studies show jumping genes more active during development of gastrointestinal cancers

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers develop new way to personalize treatments for aggressive bladder cancer

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

New endoscopic system differentiates between malignant and benign tumors in gastrointestinal tract

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

Researchers reveal cellular origin of PIK3CA-induced breast tumors

FGF protein may play key role in breast and prostate cancer, shows research

Newly developed big data technique may have significant impact on health care

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News